Clinical trial · no report yet · Phase 1
NCT06403735
A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
- NCT06403735 ↗
- Recruiting
- Qilu Pharmaceutical Co., Ltd.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of QLC1101 Monotherapy in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer; Colorectal Cancer; Pancreatic Cancer; Solid Tumor
- Interventions
- QLC1101
- Arms
- QLC1101 · Experimental
- Enrollment
- 250 (estimated)
- Primary outcomes
- Dose limiting toxicity (DLT)
- MTD (or MAD)
- RP2D
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Start
- Apr 25, 2024
- Primary completion
- May 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06403735 · updated May 8, 2024